40 results about "Antigen" patented technology

The invention discloses an integration micro-fluidic chip for immune analysis research. The chip is mainly composed of a concentration gradient generation unit, an equal allocation unit and a micropore reaction chamber matrix with the diameter of 5.8mm and the depth of 100 mu, and has small volume and large specific surface area; the arrangement of the micropore reaction chamber matrix is consistent with the arrangement of a traditional porous plate, and the micropore matrix can be applied to a standard microplate reader for detecting and gathering analysis data. According to the invention, the operations of absorption and fixation of antibodies, antigens and enzyme during immune analysis operation, the preparation of sample solutions with different concentrations, liquid replacement, washing and the other operations are all integrated on a chip and are completed automatically according to the process creatively; the reagent consumption can be lowered obviously; the analysis time can be shortened; and the efficiency can be improved. Compared with the traditional porous plate technology, according to the invention, the complex manual operations of sample solution preparation, washing and the like are omitted, and the integration micro-fluidic chip for immune analysis research is compatible with the standard microplate reader on the detecting method.

Methods of enhancing immune responses in which soluble forms of costimulatory molecules, e.g., B7 molecules, are administered to augment immune responses to antigens, e.g., to tumor cells and infectious agents are provided. The subject methods are useful for both prophylactic and therapeutic immunization of subjects.

The invention provides an ELISA (enzyme linked immunosorbent assay) kit for detecting PRRS antibody and application thereof, belonging to the field of biotechnology. The kit comprises an ELISA slat with recombinant GST-GP5 (glutathione transferase-glycoproteins) protein as coating antigen, a PBS (polydiethylene glycol sebacate) solution, a blood serum diluted solution, a rabbit anti-pig enzyme-labelled bi-antibody, a colour-developing substrate, a terminating liquor, PRRS positive blood serum, PRRS negative blood serum and the like. The kit provided by the invention is used for detecting PRRS antibody; after the indexes like specificity, sensitivity, repeatability and the like of a detection method are inspected, the method is used for detecting serum samples; and the detection coincidence rate with the ELISA kit in the prior art is 90%. The kit provided by the invention has the advantages that the operations are convenient, the repeatability is good, and the kit is suitable for being popularized and applied; a reliable measure for fast detecting PRRSV (pig progenitive and respiratory syndrome virus) antibody is supplied clinically.

The present invention belongs to the field of toxic matter detecting technology. The detection method of quickly detecting veterinary medicinal residue in food and agriculture and sideling products includes the following steps: applying coupled antigen of several kinds of veterinary medicines as micro array on solid carrier and coating; mixing deluent diluted biotinylated antibody and measured sample, competitive immunogical reaction with the coated veterinary medicinal antigen, and washing with detergent; adding avidin marked colloidal gold for amplification and colorizing, and obtaining grey result with scanning instrument. The competitive immunogical method of the present invention has the features of high sensitivity, high specificity and simple operation.

Disclosed are: a virus vector in which a gene encoding an antigenic polypeptide is integrated in human parainfluenza virus type 2 gene, wherein the antigenic polypeptide is expressed in the form of a fusion protein with a viral structural protein; and a method for producing the same. The virus vector of the present invention contains a quantitatively large amount of the antigenic peptide on the virus particle and can efficiently deliver the antigenic polypeptide to a target cell.

The invention discloses a vomitoxin quantitative determination kit and a use method thereof. The vomitoxin quantitative determination kit comprises a magnetic separation reagent 1, a resist 2, an enzyme-labelled antigen agent 3, a cleaning solution 4, a calibrator and a quality control 5, a substrate solution 6 and a stop solution 7, wherein the magnetic separation reagent is a magnetic particle suspension combined with an FITC(fluorescein isothiocyanate)-DON antibody; the resist is an FITC-labelled anti-DON antibody solution, and the enzyme-labelled antigen agent is a DON solution coupled with a biological enzyme. The vomitoxin quantitative determination kit have the remarkable advantages of simple, quick, sensitive and accurate operation, and suitability for detecting vomitoxin samples in food or feed on a large scale daily.

The invention relates to a preparation method of cyclosporin A haptin and an enzymelinked immunosorbent quantitative detection kit of the cyclosporin A, belonging to medical detection reagents. The invention mainly provides a preparation method of cyclosporin A haptin and the cyclosporin A haptin prepared by using the preparation method. The enzymelinked immunosorbent quantitative detection kit of cyclosporin A, adopting the cyclosporin A haptin, can be made into a plate-type ELISA (enzyme-linked immunosorbent assay) plate so as to adapt to popular detection equipment in China and can ensure high detection sensitivity, good stability and accurate result.

The invention provides a preparation method of monoclonal antibodies for IC (nfectious coryza) of chickens. According to the technical scheme, hybridoma cell strains secreting the monoclonal antibodies against avibacterium paragallinarum are prepared from B type strains, the secreted antibodies are only targeted at the B type strains and do not have reactions with A type and C type avibacterium paragallinarum, and accordingly, the antibodies are only targeted at B type serotype diseases. Besides, an ELISA (enzyme-linked immunosorbent assay) method and an immune colloidal gold method established according to the characteristics of the monoclonal antibodies have good specificity and sensitivity and can be used for clinical detection. Besides, the monoclonal antibodies prepared with the method are high in titer, better in specificity and especially applicable to further preparation of B type avibacterium paragallinarum antigen diagnostic kits or B type avibacterium paragallinarum antigen diagnostic colloidal gold test paper. Prominent technical effects are realized through innovative technical improvements, and the preparation method is lower in cost and easy to implement and has prominent popularization prospect.

A novel protein having inhibitory activity on the protease activity of hepatocyte growth factor (HGF) activator was purified and isolated, and its molecular weight (ca. 40,000 daltons) and its N-terminal and partial amino acid sequences were determined. A gene coding for the protein was cloned, and the gene DNA was incorporated into a vector, for transforming host cells. Cultivation of the transformant gave the desired protein. The protein can be used as an in vivo or in vitro control factor for HGF or HGF activator. It is also useful as an antigen to be used in producing an antibody to be used as means for kinetic studies of the protein, or as a standard in assay systems therefor.

The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.

The invention discloses an HCV (hepatitis C virus) core antigen, which is a polypeptide encoded by a DNA (deoxyribonucleic acid) of which the amino acid sequence is shown in SEQ ID NO.1 and the nucleotide sequence is shown in SEQ ID NO.2. The invention also discloses a hybridoma cell line secreting monoclonal antibodies, the hybridoma cell line is named as SC16-H6 and has been preserved in the China General Microbiological Culture Collection Center on July 14th, 2011, and the preservation number is CGMCC No. 5074. The invention also discloses another hybridoma cell line secreting monoclonal antibodies, the hybridoma cell line is named as SC23-G5 and has been preserved in the China General Microbiological Culture Collection Center on July 14th, 2011, and the preservation number is CGMCC No. 5075. The invention also discloses a monoclonal antibody of an anti-HCV core antigen, which is secreted by the hybridoma cell line (preservation number: CGMCC No. 5074) or the hybridoma cell line (preservation number: CGMCC No. 5075), and has a specificity to the polypeptide shown in SEQ ID No.1.

The invention provides compositions comprising and methods of using antigen presenting cells into which has been introduced at least a first nucleotide sequence that encodes calnexin, wherein expression of calnexin in the antigen presenting cell increases the antigen presenting cell's ability to activate a T cell response.

The invention discloses a kit for detecting the content of a KAPPA light chain.The kit comprises a reagent R1, a reagent R2 and a KAPPA light chain calibration material, wherein the reagent R1 comprises a first buffer solution, a first electrolyte, a surface active agent, a first stabilizer, a macromolecule accelerant and a first preservative, the reagent R2 comprises a second buffer solution, an anti-human KAPPA light chain antibody, a second electrolyte, a second stabilizer and a second preservative, and the C1 inhibitor calibration material comprises a third buffer solution, a third stabilizer, a third preservative, an antioxidant and a KAPPA light chain antigen.The invention further discloses the application of the kit for detecting the content of the KAPPA light chain and a method for detecting the content of the KAPPA light chain using the kit.By the adoption of the kit and the detection method, the content of the KAPPA light chain can be detected easily and quickly.

The invention discloses one group of nucleic acid aptamers capable of specifically bonding with tuberculosis mycobacterium Beijing genotype strain surface lipolysaccharide namely mannose modified mannosylated lipoarabinomannan (ManLAM) and application of the nucleic acid aptamers. The aptamers are specific to small-molecular single-chain DNA (ssDNA) of the ManLAM, and have a nucleotide sequence as shown in the SEQ ID No.1-5. The ssDNA has functions similar to those of a monoclonal antibody, and can be directly and specifically bonded with ManLAM. By adopting an enzyme-linked oligonucleotide assay (ELONA) method, the ManLAM antigen in serum of patients with pulmonary tuberculosis, extrapulmanory tuberculosis and the like can be quickly effectively detected in 2 hours, the ManLAM antigen in sputum of an active pulmonary tuberculosis patient can be directly identified, and the detection sensitivity on the Man LAM antigen can be 0.035mu g/mL. The aptamers are simple to prepare and low in cost, and can be used as an effective novel reagent for diagnosing the mycobacterium tuberculosis antigen of early and latent tuberculosis.

The invention relates to the technical field of genetic engineering of recombinant viruses, in particular to an application and preparation method of a candidate strain of a human type-3 adenovirus expressed human type-14 adenovirus neutralization epitope vaccine. Two human type-14 adenovirus neutralization epitopes are respectively embedded to hexons of human type-3 adenoviruses to be displayed on the surfaces of the hexons. The candidate strain of the vaccine is capable of inducing strong anti-HAdv14 and anti-HAdv3 infection immunoreactions and can be used for preparation of bivalent vaccines for prevention of HAdv14 and HAdv3 infection.

The invention relates to a recombinant chimeric antigen of treponema pallidum. The recombinant chimeric antigen is formed by connecting an amino acid sequence as shown in SEQ ID NO.12, a first flexible linker, an amino acid sequence as shown in SEQ ID NO.9, a second flexible linker and an amino acid sequence as shown in SEQ ID NO.13 in series. The recombinant chimeric antigen can be used for serological detection of treponema pallidum antibody, and has improved dissolving expression capability, activity and thermal stability. The invention also relates to a method for preparing the recombinantchimeric antigen.

An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP).

As a novel test instrument for easily semiquantifying a target substance to be measured contained in a specimen by using the immunochromatography method, it is intended to provide an immunochromatographic test instrument having a porous material in which the specimen can migrate due to the capillary phenomenon, which has: (1) an area wherein a labeled antibody or antigen capable of binding specifically to the target substance to be measured contained in the specimen is provided in the movable state; (2) an area wherein the above-described antibody or antigen capable of binding specifically tothe target substance to be measured is provided in the state of immobilized to the porous material; and (3) an area wherein a standard coloration corresponding to the coloration at a definite concentration of the target substance to be measured is provided in the state of immobilized to the porous material, and by which the target substance to be measured contained in the specimen is semiquantified by comparing the coloration in the above area (2) with the standard coloration as described above, and a semiquantitative method using this test instrument.

The invention belongs to the technical field of antigen repair equipment and particularly relates to a large-flux antigen repair instrument. The instrument comprises a water bath box body, a water bath heating tank is arranged on the inner side of the water bath box body; an automatic high-pressure sealing cover is connected to a rotating shaft at the top of the water bath box body; a plurality ofplacing tables are arranged in the water bath heating tank; a multi-connected glass slide placing rack is placed on each placing table; a heating coil, a temperature probe and a water inlet are arranged on the side of the water-bath heating tank; a water outlet is formed in the bottom of the water bath heating groove, control keys and an information display screen are arranged on the front face of the water bath box body, the heating coil, the temperature probe, the control keys and the information display screen are all electrically connected with a processing module, the upstream of the water inlet is further communicated with a water pump through a water path, and the water pump is electrically connected with the processing module. Mechanisms such as an automatic top cover, a water adding pump and a bracket for placing a large number of glass slides are designed in the water bath equipment, so that the antigen repair efficiency can be effectively improved, the operation is convenient, and the substantial characteristics are remarkable.

The invention relates to a polypeptide sequence specifically bonded with poultry bursal virus VP2 protein, and an application of the polypeptide sequence, and belongs to the field of molecular biology. Through computer-aided design, based on the crystal structure of the poultry bursal virus VP2 protein, through a molecular docking virtual screening technique, polypeptide ligands which are optimalin target protein binding mode and affinity are searched in a virtual polypeptide database, and the polypeptide sequence is SERWDN namely IBDVL9-15. Expressed and purified IBDV VP2 protein is subjected to ELISA and localized surface plasmon resonance experiment, the result indicates that IBDVL9-15 polypeptide can have favorable binding capacity with IBDV VP2 protein, and the designed polypeptide can be used for performing fast detection as well as separation and purification on IBDV VP2 antigens.

This invention provides one rapid test bar for 0139 cholera vibrio antigen, which covers 0139 cholera vibrio antibody and IgG on NC film and combines glue gold label 0139 vibrio antigen single clone antibody and applies film analysis double antibody clamper and tests label 0139 cholera vibrio antigen.

The invention provides a construction method of a mannheimia haemolytica LKTA protein prokaryotic expression vector and a kit for detecting mannheimia haemolytica. The method belongs to the technicalfield of gene engineering, and comprises the following steps: 1) carrying out PCR amplification by taking lkta-F and lkta-R as primers and taking genomic DNA of mannheimia haemolytica as a template; 2) respectively carrying out enzyme digestion on a PCR amplification product and a plasmid vector to obtain an LKTA protein coding gene enzyme digestion fragment and a plasmid vector enzyme digestion fragment; 3) connecting the LKTA protein coding gene enzyme digestion fragment with a carrier enzyme digestion fragment to obtain a recombinant plasmid; and 4) converting the recombinant plasmid into acompetent state of escherichia coli to obtain the mannheimia haemolytica LKTA protein prokaryotic expression vector. The mannheimia haemolytica LKTA protein provided by the invention has good specificity and can be used as an antigen marker for detecting mannheimia haemolytica.

The present invention discloses one kind of artificial antigen of dipropyl phthalate, which is prepared with semi-antigen derivative as shown and through diaonization with NaNO2 and concentrated HCl at low temperature to produce corresponding diazonium salt, and the coupling reaction of the diazonium salt with carrier protein. It has the structure as shown. The artificial antigen of the present invention is practical and stable, and has simple preparation process and low cost, and the present invention is easy use in industrial production.

The invention discloses a technical solution of collecting a sequence of a mycoplasma pneumoniae gene from Genbank, establishing gene data of mycoplasma pneumoniae, and analyzing the gene data throughcomputer software to obtain a segment which has detection activity of mycoplasma pneumoniae adhesion protein P1 (GenBank: AF286371.1) and adhesion protein P30 (GenBank: EF614306.1), and connecting 252nd-355th amino acids (P1A), the 898th-953rd amino acids (P1B), 1274th-1362nd amino acids (P1C), 1589th-1627th amino acids (P1D) of the P1 gene, and a P30 fragment of174th-274th amino acid of the mycoplasma pneumoniae adhesion proteinP30 in series through connecting peptides GSGSGS, wherein the sequence of connections in series is sequentially a P1A fragment-a first connecting peptide-a P1B fragment-a second connecting peptide-P1C-a third connecting peptide-P1C-a fourth connecting peptide-P1D-a fifth connecting peptide-a P30 fragment from a C terminal to an N terminal, and the corresponding nucleic acid sequence is obtained by a chemical synthesis method.

The present invention is directed to methods of suppressing the virulence of one or more virulence antigenic factors of methicillin resistant Staphylococcus aureus (MRSA). Aspects of the invention include administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of a virulence antigenic factor of MRSA attached through a linker to the aminoterminal end of the ecd CD40 ligand. The fusion protein is composed of a virulence antigenic factor of MRSA and CD40 ligand and has the ability to generate antibodies which prevents host cell infection by suppressing virulence functions of MRSA.

Disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising measuring the level of one or more polyamines in a fluid sample obtained from the subject, measuring at a variable selected from the group consisting of age, prostate volume (PV), prostate-specific antigen (PSA), digital rectal examination (DRE), and combinations thereof. Also disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising obtaining a score value based on previously disclosed variables to predict the likelihood of the subject developing or having prostate cancer.